Dianthus Therapeutics | MGTA - Operating Profit


Dianthus Therapeutics reported $-40.29M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Alaunos Therapeutics USD -1.19M 432K Sep/2025
Avita Medical AUD -11.15M 1.19M Jun/2025
Celltrion KRW 301.04B 58.57B Sep/2025
Cspc Pharmaceutical CNY 1.22B 60.54M Sep/2025
Dianthus Therapeutics USD -40.29M 5.36M Sep/2025
Divis Laboratories Ltd INR 7.75B 1.58B Sep/2025
IQVIA Holdings USD 573M 17M Sep/2025
Kangmei Pharma CNY -26.7M 43.13M Sep/2025
Knight Therapeutics CAD 3.2M 1.29M Sep/2024
Laboratorios Farma EUR 135.05M 49.84M Dec/2023
Malin Corporation EUR -1.1M 400K Dec/2024
Medical Developments International AUD -480K 662K Jun/2025
Moderna USD -260M 647M Sep/2025
Neuren Pharmaceuticals AUD 5.45M 171.24M Jun/2025
Organigram Holdings CAD -28.05M 7.76M Sep/2025
Organon & Co USD 388M 62M Sep/2025
Pharma Mar EUR -3.96M 28.06M Sep/2025
Qiagen NV USD 137.29M 1.32M Sep/2025
Revvity USD 98.34M 8.63M Sep/2025
Sartorius EUR 150.1M 11.7M Sep/2025
Sino Biopharmaceutical CNY 5.18B 3.32B Jun/2025
Tectonic Therapeutic USD -21.89M 440K Sep/2025
Tilray USD -20.01M 9.34M Sep/2025
Viatris USD 234.5M 49.1M Sep/2025
Xeris Pharmaceuticals USD 6.73M 2.25M Sep/2025
Zz Pientze Pharmaceu CNY 501.33M 52.54M Sep/2025